QuickView for SLCO2B1;jsessionid=902667E0D2FD96B250C8928B648BD13E;jsessionid=B49BAB0473496728C79E12E098B96E7D;jsessionid=89E7B74033B70C4D6478048ED23EC998;jsessionid=D2714BFBE106442621EB588AEEE01559;jsessionid=5BB0BF3128FAD86A87EA710161555500;jsessionid=F8DD57BA32ADFFEB6996BB799FFD61C4;jsessionid=3D4C57A8A2A3DC9877459623B8594D93;jsessionid=5E0B69E1519FE2C5483BA5D17E41667D;jsessionid=0733CFC48D8D54497267F25B98E2A6D9;jsessionid=3C30DD9D8504EE7380776DFF039DB287;jsessionid=CE226285C912BA0C830697407AA87553;jsessionid=2316F313918B2142CE1E6B20A5208344 (gene)

1. Metabolic-scale gene activation screens identify SLCO2B1 as a heme transporter that enhances cellula…
2. Role of Oatp2b1 in Drug Absorption and Drug-Drug Interactions.
3. Risk of Developing Hepatocellular Carcinoma following Depressive Disorder Based on the Expression Le…
4. Uremic Toxin Indoxyl Sulfate Promotes Proinflammatory Macrophage Activation Via the Interplay of OAT…
5. siRNA capsulated brain-targeted nanoparticles specifically knock down OATP2B1 in mice: a mechanism f…

There were no clinical trials for SLCO2B1;jsessionid=902667E0D2FD96B250C8928B648BD13E;jsessionid=B49BAB0473496728C79E12E098B96E7D;jsessionid=89E7B74033B70C4D6478048ED23EC998;jsessionid=D2714BFBE106442621EB588AEEE01559;jsessionid=5BB0BF3128FAD86A87EA710161555500;jsessionid=F8DD57BA32ADFFEB6996BB799FFD61C4;jsessionid=3D4C57A8A2A3DC9877459623B8594D93;jsessionid=5E0B69E1519FE2C5483BA5D17E41667D;jsessionid=0733CFC48D8D54497267F25B98E2A6D9;jsessionid=3C30DD9D8504EE7380776DFF039DB287;jsessionid=CE226285C912BA0C830697407AA87553;jsessionid=2316F313918B2142CE1E6B20A5208344